CORTCorcept TherapeuticsRunning, no new patients
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 2
- Patients
- 125 (final count)
- Started
- May 7, 2018
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Long-term safety of relacorilant
Measured over: 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03604198 · record last updated 2026-11-03 · checked 2026-11-09 15:36 UTC